Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
RVMD Stock Chart & Stats
$98.20
$0.52(1.17%)
At close: 4:00 PM EST
$98.20
$0.52(1.17%)
Day’s Range― - ―
52-Week Range$29.17 - $124.49
Previous CloseN/A
Volume180.68K
Average Volume (3M)4.28M
Market Cap
$18.82B
Enterprise Value$19.03B
Total Cash (Recent Filing)$1.93B
Total Debt (Recent Filing)$158.46M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Mar 02, 2026EPS Estimate
-1.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.61
Shares Outstanding193,319,810
10 Day Avg. Volume3,951,035
30 Day Avg. Volume4,275,724
Financial Highlights & Ratios
PEG Ratio1.69
Price to Book (P/B)3.24
Price to Sales (P/S)0.00
P/FCF Ratio-12.92
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.00K
Enterprise Value/Ebitda-19.02
Forecast
1Y Price Target
$117.57Price Target Upside19.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)-6.56
Revenue Forecast (FY)$31.11M
Bulls Say, Bears Say
Bulls Say
Combination Therapy Commercial PotentialAccelerated development of combination regimens and the potential to pair RMC-5127 with daraxonrasib could enhance efficacy, lengthen treatment durations, and support stronger commercial pricing per patient.
First-in-human MilestoneFirst patient dosing of RMC-5127, a G12V-selective inhibitor, launches clinical testing and represents a tangible execution milestone that can validate the mutant-selective approach in the pipeline.
Interim Survival AnalysesRASolute trial design allows for up to two interim overall survival analyses with management committing to rapid topline disclosure if results are unblinded, creating discrete clinical catalysts that could drive material stock moves.
Bears Say
Competitive And Clinical Outcome UncertaintyEntrenchment of competing therapies and initiation of rival studies in key lung subgroups heighten competitive hurdles, while the risk that early-phase efficacy may not replicate in randomized trials raises significant outcome uncertainty.
Financing And Dilution RiskHigh annual cash burn coupled with a large fully diluted share count increases the likelihood of future funding needs and shareholder dilution, which can weigh on valuation and investor sentiment.
Loss Of Takeover PremiumEnd of acquisition discussions removes a potential takeover premium and may trigger selling by merger-focused investors, increasing near-term stock volatility and downside pressure.
Revolution Medicines News
RVMD FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was $29.17 and its highest was $124.49 in the past 12 months.
What is Revolution Medicines’s market cap?
Revolution Medicines’s market cap is $18.82B.
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is Mar 02, 2026 which is in 31 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on Nov 05, 2025. The company reported -$1.61 earnings per share for the quarter, missing the consensus estimate of -$1.421 by -$0.189.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -1.58.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 193,319,810 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -$1.61 in its last earnings report, missing expectations of -$1.421. Following the earnings report the stock price went up 3.438%.
Which hedge fund is a major shareholder of Revolution Medicines?
Currently, no hedge funds are holding shares in RVMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revolution Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$117.57 (19.73% Upside)
$117.57 (19.73% Upside)
Blogger Sentiment
Bullish
RVMD Sentiment 60%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 684.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $450.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 12.6%
Last 30 Days ▲ 12.6%
News Sentiment
Neutral
Bullish news 54%
Bearish news 46%
Bearish news 46%
Technicals
SMA
Positive
20 days / 200 days
Momentum
139.98%
12-Months-Change
Fundamentals
Return on Equity
-60.76%
Trailing 12-Months
Asset Growth
27.73%
Trailing 12-Months
Company Description
Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
RVMD Company Deck
RVMD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong progress in clinical programs and regulatory achievements for daraxonrasib, as well as a solid financial position supported by strategic partnerships. However, these positive developments were somewhat offset by increased operating expenses and significant net losses.View all RVMD earnings summariesRVMD Stock 12 Month Forecast
Average Price Target
$117.57
▲(19.73% Upside)
Technical Analysis
Ownership Overview
2.23% Insiders
23.34% Mutual Funds
0.06% Other Institutional Investors
62.85% Public Companies and Individual Investors